Glaucoma related proteomic changes have been documented in cell and animal models. However, proteomic studies investigating on human retina samples are still rare. In the present work, retina samples of glaucoma and non-glaucoma control donors have been examined by a state-of-the-art mass spectrometry (MS) workflow to uncover glaucoma related proteomic changes. More than 600 proteins could be identified with high confidence (FDR < 1%) in human retina samples. Distinct proteomic changes have been observed in 10% of proteins encircling mitochondrial and nucleus species. Numerous proteins showed a significant glaucoma related level change (p < 0.05) or distinct tendency of alteration (p < 0.1). Candidates were documented to be involved in cellular development, stress and cell death. . In 2010, worldwide 60.5 million people suffered from glaucoma and over 70 million people are expected to develop glaucoma by 2020 making glaucoma to one of the leading causes of blindness affecting people of all ages, however with increasing prevalence with age 3 . Inflammatory 4 and autoimmune processes 5, 6 implementing oxidative stress 7 and mitochondrial dysfunction 8,9 have been documented for glaucoma so far and underlying molecular mechanisms are shifting in focus of research. Accordingly, numerous studies have demonstrated proteomic changes referring to experimental in-vivo and in-vitro models, regarding rodents 10-12 and primates 13 . Glaucoma related proteomic alterations have also been reported for human sample material, e.g. aqueous humor [14] [15] [16] [17] [18] [19] , trabecular meshwork 20,21 and tears 22 proposing key proteins and biomarker candidates. Focusing on human glaucomatous retina samples, Tezel et al. documented hemoglobin upregulation using immunohistochemistry 23 , whereas the research groups of Yang and Luo revealed proteomic changes linked to TNF-α /TNFR1 24 and Toll-like receptors (TLRs) 25 using mass spectrometry. However, proteomic investigations on human retinal sample species are rare due to limitation of donors and human sample material. Therefore, the purpose of the present study was to analyze human retinal samples of glaucoma (N = 5) and non-glaucoma subjects (N = 5) by use of a state-of-the-art "bottom-up" high performance liquid chromatography electro spray ionization mass spectrometry (BU LC ESI MS) workflow. Retinal sample exploration should provide an in-depth view to the human retina proteome, reveal glaucomatous proteomic alterations and should contribute to a better understanding of the molecular pathomechanism of glaucoma. Moreover, new molecular candidates linked to glaucomatous neurodegeneration should be proposed giving direction for future glaucoma research projects.
Glaucoma is a neurodegenerative ocular disease complex with multifactorial etiology displaying a characteristic damage pattern in the optic nerve head manifested by a progressive loss of retinal ganglion cells (RGCs), their axons and visual field 1, 2 . In 2010, worldwide 60.5 million people suffered from glaucoma and over 70 million people are expected to develop glaucoma by 2020 making glaucoma to one of the leading causes of blindness affecting people of all ages, however with increasing prevalence with age 3 . Inflammatory 4 and autoimmune processes 5, 6 implementing oxidative stress 7 and mitochondrial dysfunction 8, 9 have been documented for glaucoma so far and underlying molecular mechanisms are shifting in focus of research. Accordingly, numerous studies have demonstrated proteomic changes referring to experimental in-vivo and in-vitro models, regarding rodents [10] [11] [12] and primates 13 . Glaucoma related proteomic alterations have also been reported for human sample material, e.g. aqueous humor [14] [15] [16] [17] [18] [19] , trabecular meshwork 20, 21 and tears 22 proposing key proteins and biomarker candidates. Focusing on human glaucomatous retina samples, Tezel et al. documented hemoglobin upregulation using immunohistochemistry 23 , whereas the research groups of Yang and Luo revealed proteomic changes linked to TNF-α /TNFR1 24 and Toll-like receptors (TLRs) 25 using mass spectrometry. However, proteomic investigations on human retinal sample species are rare due to limitation of donors and human sample material. Therefore, the purpose of the present study was to analyze human retinal samples of glaucoma (N = 5) and non-glaucoma subjects (N = 5) by use of a state-of-the-art "bottom-up" high performance liquid chromatography electro spray ionization mass spectrometry (BU LC ESI MS) workflow. Retinal sample exploration should provide an in-depth view to the human retina proteome, reveal glaucomatous proteomic alterations and should contribute to a better understanding of the molecular pathomechanism of glaucoma. Moreover, new molecular candidates linked to glaucomatous neurodegeneration should be proposed giving direction for future glaucoma research projects. further inspected. Thereby, BU LC MS determination of the dynamic range of Thy-1 using recombinant protein showed a linear correlation between MS abundance and Thy-1 content between 0.15 and 0.015 μ g before and after quantification (R 2 > 0.8; p < 0.05). In the range < 0.03 μ g Thy-1 raw intensities approximate a value of 1 * E 6 generating a LFQ zero value during quantification. Moreover, in this low abundant range only one of initial five Thy-1 specific peptides is detectable, which indicate critical detection of Thy-1 < 0.03 μ g (Fig. 6) . Reanalysis of the study samples supported the presence of Thy-1 in both groups; glaucoma and control, based on raw intensities. Thereby, the protein detection corresponded to two Thy-1 characteristic peptides, which abundances could be recorded close to the detection threshold. BU LC MS analysis of a glaucoma and a control pool of remaining sample material supported identification of Thy-1 in glaucoma samples based on one characteristic peptide by MS/MS. Nevertheless, manual inspection of corresponding chromatograms also supported existence of Thy-1 in the control pool indicated by the identical diagnostic reporter peptide, however not leading to MS/MS based identification (Fig. 7) . Using Laser capture microdissection (LCM) several proteins proposed to be particularly glaucoma-associated, e.g. MeCp2, VPP1 or ANT3, could be significantly recovered (p < 0.05) from the GCL of porcine retinae utilizing the BU LC ESI MS platform (Fig. 8 , Table 1 ). Representative validation of glaucoma related proteomic changes was realized in pooled in-solution digests of retina lysates by targeted Accurate Inclusion Mass Screening (AIMS) strategy considering limited sample material ( Table 1 , Fig. 9 ). Thereby, selection of a five candidate subset including ANT3, MeCp2, DFS70, cArr and HspB5 was based on functional representation (mitochondria, nucleus, stress indication) and/or GCL support as well as on possibility of redetection of diagnostic reporter peptides in in-solution digested samples. Reporter peptides, one for each candidate protein, were preselected based on their unique amino acid sequence (Table 2) . Whereas HspB5 and cArr failed for validation, level diminishment of ANT3, DFS70 and MeCp2 could be supported by targeted AIMS analysis in pooled samples (N = 4/group) (Fig. 9 ). Despite material limitation for sufficient MS/MS fragmentation, these unique reporter peptides corresponding to MeCp2, DFS70 and ANT3 could be detected in a human non-glaucoma GCL LCM preparation also providing evidence of their presence in the human GCL (Fig. 10) . Regarding immunohistological validation of selected candidates; ANT3, DFS70 and MeCp2; all three candidates were detectable in all examined human retinae. Thereby, significant changes were observed in the overall intensity between control and glaucomatous tissue samples. ANT3 was found to be distributed in large deposits in the GCL, the inner nuclear layer (INL) and in the outer plexiform layer (OPL) and showed levels of 38.94 ± 8.2 I in control samples compared to 24.15 ± 7.8 I in glaucomatous tissue (−38%, p < 0.04) (Fig. 11A ). DFS70 occurred throughout the retina with GCL accumulations and was degraded in glaucomatous retina with 21.23 ± 1.13 I compared to 31.31 ± 1.8 I in control retina (−32%, p < 0.001) (Fig. 11B ). MeCp2 displaying accumulations in the GCL and INL showed levels of 51.85 ± 8.39 compared to 31.85 ± 9.31 in control tissue (−39%, p < 0.02) (Fig. 11C) . Moreover, STRING analysis indicated evidence for strong interaction between MeCp2 and DFS70. Also, their interaction with nucleus proteins, e.g. histone 1, high mobility group proteins (HMGs) and further proteins, e.g. endoplasmin (HSP90B1) and opticin ( Fig. 12 ) could be documented. In summary, a detailed view to the human retina proteome could be achieved providing a subset of candidate proteins showing level alterations in glaucomatous retina samples. Thereby, special evidence for glaucoma correlation could be provided for ANT3, DFS70 and MeCp2 representative for glaucoma related proteomic alterations in human retinae.
Discussion
By use of a state-of-the-art BU LC ESI approach 43 we could identify more than 600 proteins with FDR < 1%, incorporating numerous neuronal relevant protein species. Moreover, the proteomic output fits well to prior mammalian retina studies, e.g. reporting 400 proteins to be visualized from rat retina 10 , more than 900 2D gel protein spots 44, 45 and more than 800 proteins identified from mouse retina samples 46, 47 . Recently, Zhang and colleagues catalogued over 3000 retinal proteins from healthy human donors 48 . Nevertheless, proteomic investigations on human retina, especially diseased human retina samples are still rare. Ethen and colleagues identified over 500 proteins in human AMD donor retinae 49 , 72 secretory proteins were reported from human RPE cells 50 and Yang and collegues reported several hundred proteins from human retina samples 24 . Qualitatively, many of the identified retinal proteins could be supported by proteomic mammalian retina maps of other working groups focusing on rodents 51, 52 or primates 53 . Regarding the human retina proteome examined in the present work, most of the revealed proteins could be classified as intracellular species indicating a high recovery of cellular proteins in contrast to secretory or extracellular proteins. The large amount of membrane proteins probably reflects ionization priority of hydrophobic peptides in ESI experiments 54, 55 . Moreover, since retina samples in the present study were based on processed retina tissue after removing blood vessels and vitreous residuals the proteomic output can be suggested to refer to the "core proteome" of the human retina explaining a number of > 600 proteins and limited representation of secretory proteins. Regarding glaucoma affected retinal proteins, numerous candidates could be recovered from the GCL of porcine retinae by LCM analysis. "Unique" LFQ documentation of RGC specific Thy-1 in glaucoma samples was found contrary to reported reduced levels indicative for RGC loss [56] [57] [58] . Thy-1 related reanalysis showed that the protein is present in samples of both groups, control and glaucoma in low abundance and could be identified by two specific peptides, which correspond to the detection threshold < 0.03 μ g. In a further experiment with pooled samples of remaining tissue, Thy-1 could be identified in glaucoma samples by MS/MS analysis. Nevertheless, Thy-1 could be indirectly affirmed for the control group by reporter peak detection. In consequence of the low abundant recovery of Thy-1 in the study samples, Thy-1 quantification has to be viewed critical. This is a clear study limitation and has to be considered for future experimental designs. However, the detection of Thy-1, even in low abundance supports RGC representation in retinal samples. Moreover, regarding the majority of altered proteins, in first instance nucleus and mitochondrial species were found affected and could be verified to be involved in cellular key processes, e.g. transport, system development and cell death. Mitochondrial dysfunction, involvement in cell death and associated protein alteration has been intensively studied in neurodegeneration 59 including glaucoma 60, 61 . In accordance, diminishment of retinal mitochondrial proteins has been documented for neurodegenerative processes, e.g. in a Parkinson monkey 62 . Confidently, ocular levels of COX7A2, decreased in glaucoma retina samples in the present study, were found to be reduced in glaucomatous primates 63 and are involved in mitochondrial stress in POAG 64 . In this work, levels of mitochondrial ANT3 were clearly found diminished in glaucomatous retinae demonstrated by MS and immunohistology results. Moreover, ANT3 localization could be shown for the GCL of porcine and human retina fitting well with its documented high abundance in CNS neurons (www.proteinatlas.org). Lately, ANT was found to be part of the mitochondrial ATP synthasome 65 emphasizing its role for cellular energy supply. In fact, level elevation of ANT3 was reported to enhance cell survival 66 supporting its key function in glaucomatous neurodegeneration. Level declines of mitochondrial key enzymes ANT3, COX7A2, PDHE1-B and VPP1 support the entanglement of the cellular energy supply system in glaucoma 60 . Confidently, increase of ANT expression and activity has been shown to reduce cellular oxidative stress and apoptosis 67 . Furthermore, ANT3 interactions have been documented for secretogranin-1 (BiomarkerDigger: www.biomarkerdigger.org; Hit Predict: hintdb.hgc.jp), which was demonstrated to play a key role in Parkinson disease 68 . Also, interactions were reported between ANT3 and members of the tumor necrosis factor (TNF) receptor superfamily (Hit Predict: hintdb.hgc.jp) involved in glaucomatous neurodegeneration 69 . Beside mitochondrial protein alterations, levels of certain cytoplasmic proteins were found to be altered in glaucoma, e.g. cArr, which has been documented to be involved in glaucoma photoreceptor degeneration 70 and found to be diminished in AMD macula 71 . Interestingly, anti-cArr auto-antibodies have been detected in multiple sclerosis 72 supporting cArr association to neurodegenerative processes. However, even if cArr could not been validated in this work, it needs to be considered for future prospects. Additionally, further proteomic alterations can be associated to neurodegenerative processes in the retina. Glaucoma related level decrease of protein NipSnap homolog 3A is in confidence with downregulation of NipSnap proteins in Alzheimer disease 73 and hyperoxia/erythropoietin stressed brain tissue 74 . NipSnap 3 was reported to be involved in apoptosis via antagonizing x-linked inhibitor of apoptosis protein (XIAP) caspase 3 inhibition 75 . A comparable role was proposed for nucleus proteins, heterogeneous nuclear ribonucleoproteins (hnRPs) C1 and C2 76 . In accordance, a key role of hnRNP A1 in neurodegeneration was highlighted 77 . Confidently, the observed decline of hnRNP Q and U most likely refer to neuronal damages in glaucoma retinae. Diminishment of MeCp2, a retinal 48 and neuron expressed nucleus key trigger protein in Rett syndrome 78,79 fits well with its high CNS expression levels, turnover, histone modification, DNA and protein binding features as well as its level declines observed in neurodegenerative diseases 80 . Beside the neuronal key regulator function of MeCp2 in gene expression 81 , MeCp2 deficiency was suggested to affect directly the neuronal cytoskeleton 82 triggering nucleus stability, proliferation and cell viability 83 . Since there is growing evidence of MeCp2 participation in neurodegenerative pathologies 84 , Bogdanovic & Veenstra proposed a "well-balanced requirement of MeCp2 levels for proper function of the mammalian CNS" 85 , most likely encircling retinal health. Despite its high abundance in neuronal cells, which is in confidence with the supported MeCp2 retinal GCL localization in the present work, it is not known why MeCp2 level diversification exclusively affect neuronal cells 86 . Also, its high expression level and its associated role in the retina remains controversial 87 . From a functional view MeCp2 has been demonstrated to display multiple binding features to several proteins 80 , e.g. to methyl-cytosine binding domain protein 2 (MBD2) 88 or neurological relevant proteins like α -thalassemia/mental retardation, X-linked protein (ATRX) 89 and γ -synuclein 90 , which underlines its potential to modulate molecular pathways in the course of neurodegeneration. Especially, MeCp2 DNA binding and neuronal gene expression regulating features 91 give new perspective to neurodegenerative processes in the glaucomatous retina. Interestingly, DFS70 displaying glaucoma related decline, shares functional similarities to MeCp2, e.g. nucleus residence and DNA-and protein binding properties (UniProt: www.uniprot.org), suggestible for neurodegenerative involvement. Moreover, STRING interaction analysis supported strong association of MeCp2 and DFS70, both detected in the retina GCL in the present work, in confidence with their high abundance in CNS neurons (www.proteinatlas.org). Consistently, Leoh and colleagues documented direct binding of MECP2 to DFS70 92 . Misregulation of MeCp2, histone H1 and (B) Dynamic MS range of recombinant Thy-1 (50% of gel content is introduced to the LC MS system for technical reasons; therefore the X-axis displays corrected values) generated by MaxQuant software LC MS detection threshold can be determined < 0.03 μ g describing intensity values < 1* E 6 , whereby the LFQ value is calculated zero. (C). Separate evaluation of the Thy-1 specific peptides (P1-P5) indicating that for Thy-1 content < 0.03 μ g only two Thy-1 specific peptides can be detected (P1 & 3; highlighted by asterisk); which represent MS/MS identification peptides in study sample runs. Since in sample runs only two of five characteristic peptides (P1 & P3) could be detected showing raw output values < 1* E 6 , Thy-1 can be attributed to the low detection range and is consequently underrepresented in the retina samples leading to critical quantification output.
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HMGs were suggested indicative for chromatin composition changes in mouse myoblasts 93 and could reflect neurodegenerative related chromatin alterations 94 . Regarding MeCp2/HMGB1 interaction 95 , the existence of a chromatin-binding protein interaction complex affected in the glaucomatous retina is thinkable. However, the exact role of these chromatin-binding proteins has not been uncovered so far and needs to be addressed in future studies, e.g. in glaucoma animal models. Also, an indirect interaction between chromatin-binding proteins to glaucoma related proteins, opticin 96 and endoplasmin (HSP90B1) 97 , could be observed. Beside elevated endoplasmin levels, increased levels of further characteristic stress marker proteins could be detected in glaucomatous retinae, e.g. glutathione synthetase associated to the glutathione system involved in neurodegeneration 98, 99 . Furthermore, glutathione S-transferase (GST) has been described as a glaucoma associated stress marker 100 and increased serum GST immunoreactivity has been documented in glaucoma 101 . In fact, various GST species were found to be implemented to degenerative stress related pathologies [102] [103] [104] [105] . Increase of serotransferrin as an acute phase protein 106 fits well with differential expression of the protein observed in serum of glaucoma patients 107 . Also, indicative alterations of crystallins 51, 108 have been documented for diabetic retinopathy 109, 110 and glaucoma 111 and especially upregulation in retinal disorders have been reviewed 112 . Retina associated protective potential has been discussed for crystallins 113 and retinol dehydrogenase 114 , probably explaining the observed enhancements of these proteins. Exorbitant increase of crystallins was observed in the excluded glaucoma subject #G3 and consequently other stress factors beyond neurodegenerative processes cannot be precluded for crystalline increment. Decrease of 6-phosphofructokinase levels observed in glaucoma retinae is in confidence with downregulation in neurodegenerative Alzheimer 115 and Down syndrome brains 116 and supports energy metabolism implementation. Increase of α -1-antitrypsin could be indicative for elevated autoreactivity for this protein observed in serum of glaucoma patients demonstrated by our group 117 . Moreover, increase of the protein is in confidence with overexpression in serum of newly recruited glaucoma patients 107 and α -1-antitrypsin is suggestive to play a role in Alzheimer´s disease 118 . In conclusion, based on proteomic data three functional classes could be supported to be involved in glaucomatous processes: mitochondrial, stress and nucleus proteins indicating an impairment of energy metabolism, stress response and gene expression alterations in the course of retinal neurodegenerative processes. Numerous proteins could be supported to be GCL expressed revealed by LCM, underlining their involvement at the site of damage. However, the present study is limited by the number of donor retinae and sample material. Another limitation is the focus on progressed glaucoma and use of postmortem retinal material. Accordingly, the role of mitochondrial proteins like ANT3 and the function of nucleus proteins, especially hnRNPs, DFS70 and MeCp2 in the course of neurodegeneration need to be in the focus of future projects determining accurate candidate protein dynamics during glaucoma progression. In conclusion, the present work provides a sensitive image of the human "retina core proteome" supporting mitochondrial and nucleus proteome entanglement of glaucomatous neurodegeneration and highlights new molecular players, e.g. ANT3, DFS70 and MeCp2 to be considered in future glaucoma studies.
Methods
Patients and samples. Donor eyes were provided by the Cornea Bank of Rhineland-Palatine, Department of Ophthalmology, University Medical Center Mainz, Germany. Organ donations followed the guidelines for corneal donations regulated by the German Transplantation Law in agreement with the requirements of the Declaration of Helsinki. The use of remaining ocular donor tissue not required for transplantation for study purposes has been explicitly approved by the relatives of the deceased and the local ethics committee. Retina tissue samples were prepared from post-mortem donor eyes (right or left eye). Glaucoma donors (N = 5; 3 females, 2 males) were 86 + /−9 years old, control donors (N = 5; 3 females, 2 males) were 82 + /− 7 years old. For LCM experiments an additional eye bulb of a 69-year old female non-glaucoma donor was used. Donor exclusion criteria were defined as the following: any kind of ocular diseases including infection and tumors, systemic infections (viral, fungal, bacterial) incl. hepatitis, HIV, malignat neoplasia, autoimmune diseases including multiple sclerosis, Creutzfeldt-Jakob, Parkinson, Alzheimer, amyotrophic lateral sclerosis as well as need of dialysis. Ophthalmologic background and clinical history were requested from closest relatives, general practitioner and last attending doctor. Clinical phenotype of glaucoma could not be defined in donors, which is a distinct limitation of the present study. Retina tissue was extracted from eye cups (sagittal half of bulbs) and isolated from pigment epithelium, ciliar body, blood vessels and vitreous residuals in phosphate buffered saline under a binocular microscope. Liquid nitrogen snap frozen retina tissue samples were grinded by mortar and pestle, added 0.1% SDS, mixed for 20 min at room temperature and centrifuged at 14000 rpm at 4 °C. Supernatants were used for total protein measurement using the Pierce BCA Protein Assay Kit (Thermo Scientific, Rockford, USA) following the manual of the manufacturer.
BU LC ESI MS.
Retina samples (Glaucoma, N = 5; Control, N = 5; 40 μ g/sample) were run on 12% Bis-Tris 10-well prepared SDS PAGE minigels under reducing condition at 150 V followed by Coomassie Brilliant Blue staining (Invitrogen, Carlsbad, CA, USA). Sample lanes (individual and pools) were divided into 17 slices/lane followed by trypsin digestion using a modified protocol of Shevchenko et al. 119 . Dehydrated gel pieces were soaked with 100 μ l of sequencing grade modified trypsin (Promega Corporation, Madison, WI, USA) solution [15 ng/μ l] and incubated overnight at 37 °C. Lyophilized peptides were double purified by ZIPTIP C18 solid phase extraction (Millipore, Billerica, MA, USA) prior to MS analysis according to the protocol of the manufactor following lyophilization and storage − 20 °C prior to MS analysis. Resolubilized peptides (20 μ l 0.1% TFA/slice digest) were analyzed by use of LC ESI MS. The LC system consisted of a Rheos Allegro pump (Thermo Scientific, Rockford, Protein identification and quantification. Combined LC MS raw files were transferred to MAXQuant version 1.4.1.2 (Max Planck Institute of Biochemistry, Martinsried, Germany; www.maxquant.org) and its built-in Andromeda search engine for protein identification and quantification. MS/MS fragment spectra were search against the SwissProt human database (SwissProt_111101, 533049 sequences, 189064225 residues). Thereby, settings were set as follows: peptide mass tolerance = ± 30 ppm, fragment mass tolerance = ± 0.5 Da, fixed modification = carbamidomethylation (C), variable modifications: oxidation (M), acetylation (protein N-term), enzyme = trypsin, allowed missed cleavages: 2. Proteins were identified with a false discovery rate (FDR) < 1% with ≥ 6 amino acid residues and only 'unique plus razor peptides' that belong to a protein, which was also included for quantification. LFQ normalized peak intensities 120 were transferred to Statistica (Version 10, Statsoft, Tulsa, OK, USA) for group specific protein level comparison. Protein LFQ normalized peak intensities of glaucoma and control subjects were analyzed using t-test except donor sample #G3, which was excluded from analysis due to its deviated gel pattern. Proteins displaying significant group-specific level alterations (p < 0.05) or distinct tendencies (p < 0.1) were assigned candidates. For LCM analysis human as well as porcine RGC based MS raw files were combined and matched against the SwissProt human database using Proteome Discoverer version 1.1 (Thermo Scientific, Rockford, IL, USA) and MASCOT version 1.4.1.2 using a more relaxed strategy based on a 95% probability identification threshold. Functional analysis (GO and interaction analysis). Candidate proteins were inspected by gene ontology (GO) analysis using Cytoscape version 2.8.3 with integrated BINGO 2.44 plugin (www.cytoscape.org). Interaction analysis was realized by use of STRING version 10 (http://string-db.org) 121 considering a medium confidence score of 0.4 for interactions. Moreover particular candidates were manually searched for localization and interaction using online databases (www.proteinatlas.org, www.biomarkerdigger.org, Hit Predict: hintdb. hgc.jp).
Targeted MS. Validation of a selected candidate protein subset was realized by an already established in-solution tryptic digestion/LC ESI MS protocol 122 focusing on pooled samples for proper protein amount (10 μ g/subject; 40 μ g/group, N = 4/group, N = 4 technical replicates) following Accurate Inclusion Mass Screening (AIMS) strategy based on quantification of unique reporter peptides 123 , each representing one particular candidate protein. Selection of these peptides for the inclusion list was carried out manually based on the msms.txt file resulting from MaxQuant analysis. For inclusion list-dependent acquisition the use of global parent list was enabled, the dynamic exclusion segment was disabled and the m/z tolerance around targeted precursors was set ± 10 ppm. The acquired MS spectra were analyzed by MaxQuant for peptide and protein identification. Extracted spectra were searched against Uniprot/Swissprot human database using settings with peptide mass tolerance of ± 10 ppm, fragment mass tolerance of ± 0.5, peptide charge state of + 2 with FDR < 1% for identification. The output of the generated 'peptides.txt' from MaxQuant were exported in an excel workbook format (Microsoft Office Excel 2010) and the sum absolute intensity of the signature peptides for each proteins were transferred to Statistica for unpaired t-test analysis (p < 0.05).
Laser-capture microdissection (LCM).
Due to their retina model comparability 124 freshly enucleated porcine (Sus scrofa) eye bulbs (N = 3) obtained from the local slaughterhouse (Robert-Bosch-Str. 23-25, 55232 Alzey, Germany) were embedded in Tissue-Tek O.C.T. compound (Sakura Finetek, Tokyo, Japan), deep frozen in liquid nitrogen and sliced at − 27 °C to 30 μ m transversal sections using a CM 1850 cryotome (Leica Biosystems Nussloch GmbH, Nussloch, Germany). Slices were collected on UV-pretreated PEN membrane slides and transferred to cool 70% ethanol, stained with hematoxylin for 1 min and dehydrated with 70%, 96% and 100% ethanol for 2 min. RGC tissue LCM was realized by use of a PALM MicroBeam Laser system (Zeiss, Oberkochen, Germany) using 5x magnification. For each LCM extract a RGC layer tissue area on average of 5.3 mm 2 has been dissected approximately representing 19950 cells. Single cutouts had a size of 0.024 mm 2 and were captured in AdhesiveCap 500 opaque caps (Carl Zeiss Jena GmbH, Jena, Germany) under RoboLPC laser control. Tissue preparations were extracted by shaking using a KS250 Basic Intellimixer (Kika Labortechnik, Cologne, Germany) at 25 rpm and 4 °C for 2.5 h. Suspensions were transferred to BU LC ESI MS as already described. Finally, to recover candidates in human GCL, the above described LCM BU LC ESI MS workflow was applied on 30 μ m transversal sections of a single non-glaucoma donor eye bulb approximately recovering 15500 cells. Corresponding LC MS TIC chromatograms were screened for the occurrence of selected candidate (DFS70, ANT3 and MeCp2) unique reporter peptides to indicate their existence in the human retina GCL.
Immunodetection of DFS70, ANT3 and MeCp2 in retinal cross sections of healthy and glaucomatous humans. Retina specimen from sagittally split bulbi of age and gender matched donor eyes (N = 4 glaucoma, N = 4 control) corresponding to the proteomic analysis were fixed in 4% formaldehyde (Carl Roth, Karlsruhe, Germany) for 10 days before paraffin embedding by use of an automated Tissue-Tek Auto TEC embedder (Sakura Finetek, Tokyo, Japan) applying the following steps: 1. fixation, 2. dehydration, 3. clearing and 4. paraffination. For each patient, four serial cross sections with 5 μ m thickness were sliced on a 2030 Biocutrotation microtome (Reichert &Jung), transferred onto Superfrost plus slides (Thermo Scientific, Schwerte, Germany), dried and stored at 37 °C. For staining slices were dewaxed in xylene three times and rehydrated in a sequential ethanol gradient (100%, 100%, 96%, 96%, 70%, each 5 min) to Aqua dest. Antigen retrieval was performed in preheated Target Retrieval Solution (DAKO, Hamburg, Germany) at 87 °C for 30 min, followed by 20 min at room temperature before short washes in PBS (Dulbecco's PBS, Sigma Aldrich, St. Louis, MO, USA). Slices were blocked with 1% normal donkey serum/0.5% bovine serum albumin/PBS for DFS70 staining or with 3% normal goat serum/0.1%TritonX/PBS for ANT3 and MeCp2 staining for 30 min. Primary antibodies were diluted 1:200 and incubated at 4 °C overnight. Spare antibodies were washed off using PBS twice for 15 min on a rotating platform. were conducted through incubation of equally treated slides with secondary antibodies exclusively. For quantification mounted tissue was photographed immediately after staining using Eclipse TS 100 microscope with a DS-Fi1-U2 digital microscope camera and an ELWD 20x/0.45 S Plan Flour Ph1 ADM objective and recorded by the imaging software NIS Elements version 4.10 64 bit (microscope, camera, equipment and software were purchased from Nikon, Tokyo, Japan). Exposure time settings were the same for samples from healthy and glaucomatous patients. At least 30 pictures were taken per patient for analysis. Quantification of intensity differences was performed using Image J (rsb.info.nih.gov/ij, NIH, Bethesda, MD, USA) and statistical differences in the overall intensity (I) were calculated by using Breakdown ANOVA Test and unpaired t-test in Statistica.
Focused Thy-1 analysis. Dynamic range of recombinant human Thy-1 (P01, Ref. H00007070-P01, Abnova, Heidelberg, Germany) was determined by use of the established BU LC MS workflow encircling 1D-SDS PAGE and LC MS. At first, three identical sample dilution subsets of Thy-1 were run on three gels allowing triplicate analysis of each Thy-1 dilution in the LC MS system. In-gel digestion and ZIP TIP purification of Thy-1 dilution samples were carried out as already described. Accordingly, triplicate samples of 0.15, 0.12, 0.09, 0.03, 0.015 μ g Thy-1 were analyzed by the LC MS system following MaxQuant analysis considering MaxQuant Raw and LFQ data acquisition. Mean MaxQuant Raw and LFQ intensity values of Thy-1 triplicate LC MS measurements were transferred to Statistica (version 10, Statsoft, Tulsa, OK, USA) for dynamic range determination by linear regression analysis. Furthermore, for validation of Thy-1 regulation, LC MS TIC raw files corresponding to Thy-1 SDS PAGE mass migration area of the control and the glaucoma sample pool (40 μ g/lane) were analyzed by ProteomeDiscoverer and manually inspected for occurrence of Thy-1 specific unique peptide corresponding to 856.46 m/z.
